Achieving a better cure for cancer

CiMaas is a Biotech company based in Maastricht
the Netherlands
A city known for its international collaborations

TEAM
Prof dr. Gerard M.J. Bos
CEO, CMO, founder
Dr Wilfred T.V. Germeraad
CSO, COO, founder
Dr Yvo M.F. Graus
CBO



ADVISORY BOARD
Drs Daan van den Noort, MD
Advisor on business development, financing and strategy.

SCIENTIFIC ADVISORY BOARD
Prof dr Joachim Aerts
Pulmonologist and Medical Oncologist at the Erasmus Medical Centre in Rotterdam.

Prof dr John Haanen
Internist with emphasis on Medical Oncology in the Antoni van Leeuwenhoek (AVL) as well as investigator at the department immunotherapy of the Dutch Cancer Institute in Amsterdam.

The problem and our challenge

Current anti-cancer therapies cure about 60% of all patients in the Western world. Therefore, cancer is still a leading cause of death in most industrial countries. Immunotherapy is a promising opportunity to further limit the number of people that succumb from cancer in the future. It is CiMaas' perspective to add valuable years to the lives of people with cancer by making use of the immune system.

New therapeutic concepts as solution to fight cancer

Inspired by nature, CiMaas will bring two aspects of the immune system together to enhance the killing capacity of the system as a whole: inducing anti-cancer capacity by killer cells and strengthen this cell response by the use of antibodies, like nature does (Figure 1). It will do so for several types of cancer, to start with lung cancer, breast cancer and multiple myeloma, diseases with unmet needs. The technologies can be applied to a wide range of other cancers.

- The CiMaas tumor target dendritic cell vaccination platform provides extremely potent and **patient specific** dendritic cells that can effectively prime a specific anti-tumor T cell immune response with tumor cell-killing capacity. CiMaas will actively explore the **synergy** between marketed immune cell checkpoint inhibitor monoclonal antibodies that enhance the immune response of the patient.

- The CiMaas NK cell expansion technology provides the capability for the treatment of cancer patients using very high numbers of **donor** derived Natural Killer cells ("NK cells") that have a strong potential to kill tumor cells, already proven in several pre-clinical models. They will become available as of-the shelf product. For expansion of NK cells, CiMaas works closely together with collaborators in the USA.

Investment details
A round realised in 2016
B round foreseen in 2018

Company exit: several



Figure 1: The CiMaas vision on engaging the full potential of the immune system in the battle against cancer. A) Dendritic cells will activate tumor specific T cells and by taking of the brake of these T cells, by blocking with check-point inhibitors, the T cells will not exhaust, and B) donor NK cells that are active by themselves will be targeted to tumors and further activated in the presence of antibodies.

Our team

The CiMaas executive team has expert knowledge and experience in immunology research, clinical oncology, biotech business, as well as finance and works with an expert network to realize the company's goals. CiMaas operates as a highly efficient integrated biotech and collaborates with several strategic partners including CytoSen, bioreactor equipment manufacturers Miltenyi and Zellwerk. CiMaas has a cleanroom facility within the matrix of InSciTe.

Generating value for patients and shareholders

CiMaas' technology will make present available technologies (antibodies) more efficacious and the combined treatment more cost-effective and as such creating added value for patients, partners and shareholders. Our technology will be developed and approved likely within 6 years after start of phase I/II trials, creating patient benefit and financial return in a relatively short time frame in this industry. Given the broad applicability of CiMaas' technology for a range of cancers, it represents an enormous (commercial) potential.

For further information please contact us:
E: info@cimaas.com

Gerard MJ Bos, CEO
T: +31-6-10711914
E: gerardmjbos@cimaas.com

W: www.cimaas.com

Addresses:
Main office
Oxfordlaan 70, 6229 EV Maastricht | P.O. Box 1036, 6201 BA Maastricht, the Netherlands

GMP facility
InSciTe, Urmonderbaan 20f
6167 RD Geleen, the Netherlands